The Royalty rate (high teens) is unfortunately the best case. I am not sure how attainable it is... On the other hand the 30% if my quick read of the 8-k is right would be in addition to (lower) royalty.
It’s much more than a hope, IMO, because it doesn’t make sense for MNTA to decline the opt-in on FoB’s where MNTA itself did the reverse engineering to make the programs viable.
The only way I could see MNTA declining the opt-in on compounds #3-#6 is if MNTA’s cash balance were expected to be drastically reduced as a result of losing the patent case against Amphastar.
Market Data 
Markets 
AI
